Page Title
Clinical Trial Finder
Ask About Participating in This Study
Restore CFTR ProteinCompleted with Results
Phase 2 study of PTI-808 triple-combination therapy in adults with cystic fibrosis who have at least one copy of the F508del mutation, protocol number PTI-808-01The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
Restore CFTR ProteinCompleted with Results
Phase 2 study of PTI-808 triple-combination therapy in adults with cystic fibrosis who have at least one copy of the F508del mutation, protocol number PTI-808-01
This study evaluated the effectiveness and safety of the drug, PTI-808 in combination with PTI-801, with or without PTI-428. This study was for people with CF ages 18 and older who have at least one copy of the F508del CFTR mutation.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
9
-
Length of Participation:
10 weeks
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More